Gilles Marchal

This inventor holds 16 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Institut Pasteur, National Institute of Health and Medical Research, National Institute for Agricultural Research. Active years: 1997-2013.

USPTO Granted Patents = 16 (Patent Applications = 2)

% Patents Active = 50.0

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 3.8

ph-index = 2

Forward Citations = 38(Granted Patents)

Location History:

Ivry S/Seine, FR (1997)
Ivry, FR (1999 - 2000)
Ivry Sur Seine, FR (1998 - 2013)
Paris, FR (2013)

Company Filing History:

National Institute of Health and Medical Research

patents

1 out of 285

National Institute for Agricultural Research

patents

where one patent can have more than one assignee

Years Active: 1997-2013

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8414865 - [object Object] (2013-04-09),

2. 8404250 - Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation (2013-03-26),

3. 7871627 - Gram positive bacteria preparations for the treatment of disease comprising an immune dysregulation (2011-01-18),

4. 7820142 - Immunogenic glycopeptides, screening, preparation and uses (2010-10-26),

5. 7658929 - Immunogenic glycopeptides, screening, preparation and uses (2010-02-09),

6. 7361348 - Immunogenic glycopeptides, screening, preparation and uses (2008-04-22),

7. 7101555 - Mycobacterial proteins, microorganisms producing them and their use for vaccines and the detection of tuberculosis (2006-09-05),

8. 6676945 - Mycobacterial proteins, microorganisms producing them and their use for vaccines and for the detection of tuberculosis (2004-01-13),

9. 6379902 - Mycrobacterial proteins, microorganisms producing same and uses of said proteins in vaccines and for detecting tuberculosis (2002-04-30),

10. 6335181 - Mycobacterial proteins, microorganisms producing them and their use for vaccines and for the detection of tuberculosis (2002-01-01),

11. 6221353 - Antibodies Which Bind Mycobacterial Tuberculosis Proteins (2001-04-24),

12. 6060259 - Mycobacterium proteins and applications (2000-05-09),

13. 5962240 - Mycobacterium proteins and applications (1999-10-05),

14. 5866130 - Mycobacterial proteins, microorganisms producing them and their use for (1999-02-02),

15. 5714593 - DNA from mycobacterium tuberculosis which codes for a 45/47 kilodalton (1998-02-03),

Title: Innovations by Gilles Marchal: Pioneering Research in Atherosclerosis and Immune Dysregulation

Introduction

Gilles Marchal is a remarkable inventor based in Ivry-sur-Seine, France. With a prolific portfolio of 16 patents, he has made significant contributions to the fields of medical research and therapeutics. His innovations focus on treating complex health conditions, particularly through novel bacterial applications.

Latest Patents

One of Gilles Marchal's latest patents involves the use of BCG (Bacillus Calmette-Guérin) that has been killed by Extended Freeze Drying (EFD) for preventing or treating atherosclerosis. This innovative approach showcases the potential of harnessing bacterial products to address cardiovascular diseases. Another noteworthy application relates to Gram-positive bacteria preparations for treating diseases associated with immune dysregulation. This patent delves into the composition of components derived from Gram-positive facultative intracellular bacteria for the treatment of disorders in both humans and animals, highlighting his commitment to advancing medical science.

Career Highlights

Throughout his career, Gilles has been associated with esteemed research institutions such as the Institut Pasteur. His work at these institutions underscores his dedication to exploring uncharted territories in biomedical research and the development of therapeutic solutions.

Collaborations

Gilles Marchal has had notable collaborations with esteemed colleagues, including Felix Romain and Pascale Pescher. These partnerships reflect his ability to work within multidisciplinary teams to foster innovation and enhance the impact of his research endeavors.

Conclusion

Gilles Marchal's contributions to the field of medical inventions are a testament to his innovative spirit and commitment to improving healthcare outcomes. His latest patents not only hold promise in addressing critical health issues but also exemplify the importance of collaborative research in advancing scientific knowledge. With his continuous efforts, Gilles Marchal remains a key figure in the realm of medical inventions.